Oasis Diagnostics® Corporation was founded in 2002 to address a growing need for non-invasive saliva based technology for rapid testing, sample collection, and molecular diagnostics [DNA, RNA and proteins]. The Company is dedicated to meeting the need for more effective screening tools, which may be applied to the early detection of diseases and medical disorders, utilizing non-invasive test specimens, particularly oral fluids (saliva).
Oral Fluid Products
A major focus area for the company is our commitment to providing timely and superior quality diagnostic and screening solutions. Oasis Diagnostics® Corporation has developed a unique proprietary range of oral fluid products which includes the *VerOFy® oral fluid rapid test platform, the *Versi•SAL® split sample saliva / oral fluid collection device, the DNA•SAL™ Salivary DNA collection device, and Super•SAL™, a novel device for RNA and or protein collection for genomic applications or proteomics and the Sali•Chek™ hand held electronic reading device for lateral flow test reading. Additional devices are under development.
The Company is also the exclusive North American distributor for a novel genomic product line from ViennaLab Diagnostics (Vienna, Austria), which is based upon pharmacogenomics and genetic predisposition. Products include rapid strip based assays for KRAS mutations, BRAF, Fc Gamma Receptors, Congenital Adrenal Hyperplasia [CAH], hemochromatosis, Alzheimer's disease, cardiovascular disease (CVD), Familial Mediterranean Fever (FMF), Gaucher's disease, sugar (glucose / fructose) intolerance, CYP2D6, HLA-B27, cystic fibrosis and others.
Newer pharmacogenomic tests include novel immunoassays for identification of genotypes associated with response to Coumadin anti-coagulants including Warfarin, treatment response to HIV HAART and 5-fluorouracil chemotherapy treatment response. Recently the Company announced a partnership to distribute products from Operon S.A. ( Zaragoza, Spain). Products in this range include strip format genomic tests for celiac disease and AZF micro-deletions in chromosome Y for male fertility.
Oasis Diagnostics® Corporation was founded on the philosophy that "early detection is the key to disease prevention efforts," so we are constantly searching for innovative new products and potential partners from many parts of the world, which fit into this strategic directive with the single purpose of improving the quality of healthcare for our global customers.
With this particular emphasis in mind, Oasis Diagnostics® Corporation is always open to discussing new business opportunities with potential collaborative partners, which fit into our Corporate strategy. Sali•Chek™, VerOFy®, DNA•SAL™, Versi•SAL®, 4saliva®, Super•SAL™ and Oasis Diagnostics® are trademarks of Oasis Diagnostics® Corporation. These devices are the subject of a series of US and international patent submissions and issued patents.